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tropic hormone GLP2 are released from enteroendocrine L cells in
response to ingested nutrients. Treatment with an exogenous
GLP2 analogue increases intestinal villous mass and prevents
intestinal injury. Since GLP2 is rapidly degraded by dipeptidyl
peptidase 4 (DPP4), DPP4 inhibition may be an effective treatment
for intestinal ulcers. We measured mRNA expression and DPP
enzymatic activity in intestinal segments. Mucosal DPP activity
and GLP concentrations were measured after administration of
the DPP4 inhibitor sitagliptin (STG). Small intestinal ulcers were
induced by indomethacin (IM) injection. STG was given before IM
treatment, or orally administered after IM treatment with or with
out an elemental diet (ED). DPP4 mRNA expression and enzymatic
activity were high in the jejunum and ileum. STG dosedependently
suppressed ileal mucosal enzyme activity. Treatment with STG
prior to IM reduced small intestinal ulcer scores. Combined treat
ment with STG and ED accelerated intestinal ulcer healing, accom
panied by increased mucosal GLP2 concentrations. The reduction
of ulcers by ED and STG was reversed by coadministration of the
GLP2 receptor antagonist. DPP4 inhibition combined with luminal
nutrients, which upregulate mucosal concentrations of GLP2,
may be an effective therapy for the treatment of small intestinal
ulcers.
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IntroductionThe gut incretin hormones, glucagon-like peptide-1 (GLP-1) and
gastric inhibitory polypeptide/glucose-dependent insulinotropic
peptide (GIP), are released from enteroendocrine cells in response
to ingested nutrients and augment insulin secretion.(1) Although
GLP-1 like peptides are used therapeutically to treat type 2
diabetes, native GLP-1 is rapidly degraded and deactivated by
dipeptidyl peptidase-4 (DPP4).(2) Gliptin inhibitors of DPP4
activity such as sitagliptin (STG), vildagliptin, and saxagliptin,
work by slowing incretin metabolism, increasing endogenous
GLP-1 concentrations, and improving post-prandial glycemic
control in type 2 diabetes.(3,4)
Another processing product of proglucagon, GLP-2 is also a
DPP4 substrate. GLP-2 is a pleiotropic hormone that affects
multiple facets of intestinal physiology, including epithelial
growth, barrier function, digestion, absorption, motility, and blood
flow.(5,6) Since GLP-2 exerts potent trophic and anti-apoptotic
effects in the gastrointestinal tract and improves intestinal absorp-
tion, GLP-2 is an attractive target for development of novel
treatments for intestinal diseases.(7,8) The stable GLP-2 analogue
teduglutide significantly increases intestinal wet weight and
improves nutrient absorption in short bowel syndrome patients,(9)
although teduglutide therapy is somewhat risky and quite costly.
Since GLP-2 is also rapidly degraded and deactivated by DPP4,
DPP4 inhibition has also been considered as a novel approach for
the treatment of inflammatory bowel disease based on experi-
mental and clinical studies.(10–13) However, the effects of DPP4
inhibition on other forms of intestinal damage such as ulcers due
to non-steroidal anti-inflammatory drugs (NSAIDs) have not been
extensively explored. Although GLP-2 induces its intestinotrophic
effects through endocrine and paracrine mechanisms, the potential
mucosal protective effect of local GLP-2 has not been explored.(5,14)
Furthermore, the effects of DPP4 inhibitors on intestinal GLP
concentrations and DPP4 activity have not been studied.
NSAIDs such as low-dose aspirin are widely used to reduce the
risk of cardio- and cerebrovascular thrombosis.(15,16) However,
NSAIDs often induces gastroenteropathy by increasing the perme-
ability of mucosa.(17,18) So far, various drugs such as misoprostol,
sulfasalazine, anti-biotics, and polaprezinc has been considered to
be candidate drugs to NSAID-induced intestinal injury.(19) And it
is reported that combined treatment with rebamipid and proton
pomp inhibitor omeprazole prevented NSAID-induced gastroin-
testinal symptoms.,especially lower gastrointestinal symptoms.(20)
Although potent anti-secretory therapy can prevent NSAID-
induced foregut mucosal injury, the usefulness of proton pomp
inhibitor is still controversial.(21)
We recently reported that exogenous GLP-2 or a DPP4 inhibitor
prevented ulcer formation and promoted healing of NSAID-
induced intestinal ulcers in rats.(22) Furthermore, DPP4 inhibition
with amino acids and a nucleotide umami taste receptor (TAS1R3)
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ligand accelerated intestinal ulcer healing, suggesting that DPP4
inhibition combined with luminal amino acids enhances GLP-2-
related mucosal protection, thus preventing ulceration and pro-
moting healing of NSAID-induced enteropathy.
Therefore, we further hypothesized that the clinically used
DPP4 inhibitor STG prevents intestinal ulcers and promotes ulcer
healing by inhibiting mucosal DPP4, which increases mucosal
GLP-2 concentrations. We also examined the effect of an elemental
diet (ED), which is used therapeutically for Crohn’s disease
patients,(23,24) on healing of NSAID-induced intestinal ulcers.
Materials and Methods
Animals. Six-week-old male BALB/c mice (CLEA Japan,
Tokyo, Japan) weighing 20–25 g and six-week-old male SD rats
(Oriental Bio Service, Inc., Kyoto, Japan) weighing 200–250 g
were used in this study. The animals were maintained in an animal
colony with controlled temperature (23°C) and light (12 h light–
dark cycle) at the Osaka Medical College, Osaka, Japan, and were
permitted free access to standard mouse or rat chow pellets (MM-3,
Funabashi Farms, Chiba, Japan) and tap water. Ethical permission
for the experiments presented in this study was given by the
Animal Ethical Committee of the Osaka Medical College and all
procedures were conducted according to the guidelines of the
Institute for Laboratory Animal Research at Osaka Medical College.
Chemicals and elemental diets. The DPP4 inhibitor STG
phosphate monohydrate was purchased from Carbosynth Limited
(Berkshire, UK). STG phosphate monohydrate was dissolved in
distilled water and given to mice by oral gavage at a dose of
0.3, 1, or 3 mg/kg. Another DPP4 inhibitor, K-579, was obtained
from Tocris Bioscience (Ellisville, MO). K-579 was dissolved
in dimethyl sulfoxide at a concentration of 0.1 M to make a stock
solution. GLP-23-33 was synthesized by Operon Biotechnologies,
K.K. (Tokyo, Japan). Elental® (Ajinomoto Co., Inc., Tokyo, Japan)
was used as the elemental diet, and contains essential amino
acids as the sole source of nitrogen. Indomethacin (IM) and other
chemicals were obtained from Sigma Chemical (St. Louis, MO).
IM was freshly dissolved in ethanol.
Analysis of DPP4 mRNA expression by realtime PCR.
To evaluate segmental differences in mucosal DPP4 mRNA
expression in mouse intestine, scraped mucosal samples were
removed from the duodenum, jejunum, ileum, proximal colon
(PC), and distal colon (DC), frozen in liquid nitrogen, and stored
at –80°C until RNA isolation. Total RNA was extracted using an
RNeasy mini-Kit (Qiagen in Japan, Tokyo, Japan). RNA was
reverse-transcribed with a Prime Script RT reagent Kit (Takara
Bio Inc., Shiga, Japan) with a SYBR Premix Ex Taq Kit (Takara)
using a Thermal Cycler Dice Real Time System TP870 (Takara).
Sequences of the sense and antisense primers for mouse DPPs and
β-actin were as follows: DPP4: 5'-AAATGGGATTTGTGGACA-
GCAAG-3' and 5'-CCGATCCCAGGACCATTGAG-3'; DPP8:
5'-GCGGTAAGCTGATCCCTGACA-3' and 5'-CCAGCCAGC-
ACTTGAAAGCTC-3'; DPP9; 5'-TCATCCACAAGCCACAAG-
TGTTC-3' and 5'-GGGCTACAGACCCTGCCTCATA-3'; β-
actin: 5'-CATCCGTAAAGACCTCTATGCCAAC-3' and 5'-
ATGGAGCCACCGATCCACA-3'. Cycling conditions were as
follows: 1 cycle of 95°C for 30 s for denaturing followed by 40
cycles of 95°C for 5 s; 60°C for 30 s, 1 cycle of 95°C for 15 s, and
60°C for 30 s. The expression of target genes was normalized to
expression of β-actin.
Mucosal DPP activity. Mice were assigned to groups re-
ceiving either sitagliptin (0.3, 1, or 3 mg/kg) or 0.2 ml of saline
vehicle via oral gavage. Mice were sacrificed 24 h after STG
administration. Mice were freely fed until euthanasia. Mucosal
scrapes of each intestinal segment were collected in homogeniza-
tion buffer (Tris-buffered saline) containing protease inhibitors
(Complete Mini, Roche Diagnostics, Indianapolis, IN). Blood
samples were collected into chilled Eppendorf tubes containing
1 μl of 0.5 M EDTA. The homogenate and blood samples were
immediately centrifuged at 3,000 × g for 5 min, and supernatants
or plasma were stored at –80°C until measurements were taken.
Mucosal DPP activity was determined by the cleavage rate of
7-amino-4-methylcoumarin (SensoLyte AMC DPP4 Assay Kit,
AnaSpec, Inc., Fremont, CA) from the synthetic substrate; this
assay was performed according to the manufacturer’s instructions.
In brief, mucosal lysate containing 10 μg/50 μl of protein was
mixed with 50 μl of DPP substrate AMC (AnaSpec). After 30 min
of incubation at room temperature, cleaved AMC was measured
using a fluorescence plate reader with excitation at 354 nm
and emission at 442 nm (Fluoro Skan Ascent, Thermo Fisher
Scientific K.K., Kanagawa, Japan). Mucosal DPP activity was
expressed as relative fluorescence units (RFU).
Measurement of plasma and mucosal GLPs. Plasma and
mucosal homogenates were processed in the presence of K-579
(final concentration 0.1 mM) as described above. Plasma and
mucosal concentrations of active GLP-17-36 and total GLP-2 were
measured using a GLP-1 (Active 7-36) ELISA kit and a GLP-2
(Mouse) ELISA kit (ALPCO Diagnostics, Salem, NH) according
to the manufacturer’s instructions.
Immunohistochemistry and immunoblot analyses. Ex-
pression of single-stranded DNA (ssDNA) in the intestinal
mucosa was assessed by the labeled streptavidin-biotin method
using an LSAB kit (Dako Japan, Tokyo, Japan) with microwave
antigen retrieval. The ileum was fixed in 10% formalin, paraffin-
embedded, and cut into 4-μm tissue sections. The sections were
mounted on microscope slides, deparaffinized in xylene, and
dehydrated with 100% ethanol. After washing with PBS, sections
were placed in 10 mM citrate buffer (pH 6.0) and heated to 80°C
for 10 min in a microwave oven. Endogenous peroxidase activity
was blocked using 0.3% hydrogen peroxide in 10% methanol for
30 min, followed by incubation with blocking reagent for 15 min.
Sections were incubated at 4°C overnight with rabbit anti-ssDNA
antibody (Dako). After washing with PBS, sections were incubated
with biotinylated anti-rabbit IgG (Dako) at room temperature for
30 min. Sections were then visualized using streptavidin-biotin
horseradish peroxidase (Dako) and 3,3' diaminobenzidine (Dako).
Sections were counterstained with hematoxylin, dehydrated, and
cover-slipped with permanent mounting medium for microscopic
observation.
Lysates of ileal mucosa containing 20 μg/20 μl of protein were
separated by electrophoresis through a NuPAGE in 4–12% Bis-
Tris Gel 1.0 mm (Life Technologies, California, USA), and
transferred onto polyvinylidene difluoride membranes (Pall
Corporation, New York, NY). Membranes were incubated in 5%
skim milk in Tris-buffered saline with Tween 20 (TBST) at room
temperature for 10 min and stored at 4°C overnight. After washing
3 times in TBST, membranes were incubated with rabbit anti-
cleaved caspase-3 antibody (Cell Signaling Technology Japan,
Tokyo, Japan) and mouse anti-β-actin antibody (Sigma) for 1 h at
room temperature in 5% skim milk. Membranes were washed 3
times in TBST and incubated with peroxidase-conjugated
secondary antibodies (Santa Cruz Biotechnology, Dallas, TX).
Blots were washed 3 times with TBST and developed using an
enhanced chemiluminescence system (ECL Prime Western Blotting
Detection System, Buckinghamshire, UK, and FUJIFILM Imaging
System Application Note LAS-3000, FUJIFILM, Tokyo, Japan).
Effects of STG on indomethacininduced intestinal injury.
For the ulcer prevention study, small intestinal ulcers were
induced by IM treatment (10 mg/kg/day, s.c.) in fed rats on Day 0
as previously described.(22) The DPP4 inhibitor STG (1 or 3 mg/kg)
was given orally for 2 days at 24 h and 0 h before IM treatment.
Rats were sacrificed 24 h after IM treatment. The small intestine
was divided into 7 segments from duodenum to ileum, and
longitudinal ulcer length was measured in each segment as pre-
viously described.(22) Total ulcer length was expressed as total
ulcer score. To identify the effects of endogenous active GLP-2,
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GLP-23-33 (100 μg/kg/day, s.c.) was administered to STG-treated
rats on Day –1 and Day 0 before IM treatment.
For the ulcer healing study, small intestinal ulceration was
induced by IM treatment (8 mg/kg/day, s.c. for 2 days) in fed rats
as reported previously.(8) STG (3 mg/kg/day) was administered
orally from Day 2 to Day 8 after IM treatment. For ED treatment,
free access to powdered ED instead of standard chow diet was
provided daily. Vehicle-treated control animals were given
powdered standard chow diet. Rats were euthanized 7 days after
IM treatment (Day 8). To identify the effects of endogenous
active GLP-2, GLP-23-33 (100 μg/kg/day, s.c.) was administered
to rats co-treated with STG and ED from Day 2 to Day 8 after
IM treatment.
Statistics. All data are expressed as means ± SD. Data were
derived from six animals in each group. Comparisons were per-
formed using one-way ANOVA or Kruskal-Wallis followed by
Fisher’s PLSD test. Statistical significance was defined as p<0.05.
Results
Mucosal DPP4 mRNA expression and enzyme activity in
murine intestine. We first examined segmental differences in
DPP mRNA expression in normal murine intestine. Consistent
with previous reports,(25,26) real-time PCR analysis revealed the
highest DPP4 mRNA expression in the jejunum and ileum,
whereas expression was low in the PC and DC (Fig. 1A). Other
DPP gene family members, DPP8 and DPP9, were predominantly
expressed in the colon, but less so in the duodenum and small
intestine (Fig. 1B and C). Another DPP, fibroblast activation
protein, was not detected in any intestinal segment tested (data
not shown).
Next, we measured mucosal DPP activity in the duodenum,
jejunum, ileum, and colon. Although DPP8, DPP9, and FAP have
activity similar to DPP4, the DPP activity assay revealed that the
distribution of enzyme activity and DPP4 mRNA expression were
highly correlated (Fig. 2), suggesting that DPP activity measured
in each segment corresponds to DPP4 expression.
Fig. 1. Mucosal DPP mRNA expression in the duodenum, jejunum, ileum, proximal colon (PC), and distal colon (DC). mRNA expression of DPP4 (A),
DPP8 (B), and DPP9 (C) was measured and expressed relative to βactin. Values were expressed as means ± SD. *p<0.05 vs duodenum, †p<0.05 vs
jejunum, ‡p<0.05 vs ileum.
Fig. 2. DPP enzymatic activity in the duodenum, jejunum, ileum, PC,
and DC. DPP activity in mucosa from each area was expressed as relative
fluorescence units (RFU). *p<0.05 vs duodenum, †p<0.05 vs Jejunum,
‡p<0.05 vs ileum.
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Effects of STG on plasma and mucosal DPP4 activity in
mouse intestine. The effects of STG (0.3–3 mg/kg, i.g.) on
plasma and mucosal DPP4 activity were measured 24 h after
treatment (Fig. 3). Although plasma DPP4 activity (data not
shown) and mucosal DPP4 activity were not significantly reduced
in mouse colon 24 h after treatment, oral administration of STG
dose-dependently suppressed mucosal DPP activity in the jejunum
and ileum.
Effects of STG on plasma and mucosal GLP concentrations
in mouse intestine. Plasma concentrations of GLP-17-36 were
significantly higher in STG-treated mice than in vehicle-treated
mice (Fig. 4). STG also significantly increased mucosal GLP-17-36
concentrations in the ileum and PC (Fig. 4). However, STG treat-
ment did not affect plasma or mucosal total GLP-2 concentrations
(Fig. 5).
Preventive effects of STG on IMinduced intestinal ulcers
in rats. Pretreatment with STG (3 mg/kg, i.g., for 2 days on
Days −1 and 0) reduced intestinal ulcers compared to the
vehicle + IM group (Fig. 6A and B). STG dose-dependently
reduced ulcer scores (Fig. 6D). Co-administration of GLP-23-33
(100 µg/kg/day, s.c., for 2 days on Days –1 and 0) partially reversed
the preventive effect of STG on ulcer formation (Fig. 6C and D).
Immunohistochemical examination revealed increased ileal
ssDNA staining after IM treatment, which was suppressed by
pretreatment with STG (Fig. 7A–C). Furthermore, Western
blotting revealed that expression of cleaved caspase-3 was also
reduced in the ileum in the STG + IM group (Fig. 7D).
The healing effect of STG and ED on IMinduced intestinal
ulcers. Seven days after IM treatment, ulcers remained present,
mostly in the ileum. Daily treatment with ED after IM treatment
significantly reduced the ulcer score compared to the IM + vehicle
group (Fig. 8). Although STG alone had no significant healing
effect on intestinal ulcers, ED with STG treatment promoted ulcer
healing. Co-administration of GLP-23-33 (100 μg/kg/day, s.c., Day
2 to 8) partially reversed ED + STG-induced healing of intestinal
ulcers. During healing, IM treatment reduced total GLP-2 concen-
trations in the ileal mucosa (Fig. 9). ED and ED + STG treatment
significantly increased mucosal total GLP-2 concentrations,
whereas STG alone had no significant effect.
Fig. 3. Effects of sitagliptin (STG) on mucosal DPP enzyme activity in the duodenum, jejunum, and colon. DPP enzymatic activity was measured in
intestinal segments from vehicle or STGtreated mice (0.3–3 mg/kg, ig). *p<0.05 vs vehicle.
Fig. 4. Effects of sitagliptin (STG) on GLP1736 concentrations in plasma, and duodenum, jejunum, ileum, and proximal and distal colon in mice.
*p<0.05 vs vehicle.
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Discussion
We demonstrated that the DPP4 inhibitor STG suppressed
mucosal DPP4 activity and increased mucosal concentrations of
GLP-17-36 in the ileum and proximal colon, accelerating intestinal
ulcer healing. We also report that feeding an elemental diet
increased ileal mucosal concentration of total GLP-2. Further-
more, STG administration prevented ulcer formation, and when
combined with ED treatment, accelerated healing of IM-induced
intestinal ulcers via a GLP-2 pathway, consistent with our recent
study.(22) We have previously reported that DPP4 inhibition
potentiated the effects of luminal nutrients, such as amino acids,
via a GLP-2 pathway, and suggested that the modulation of the
local concentration by release of the endogenous hormone GLP-2
by luminal compounds and DPP4 inhibition provide mucosal
protection.(27,28) Taken together, these findings indicate that DPP4
Fig. 5. Effects of sitagliptin (STG) on plasma and mucosal concentrations of GLP2 in mouse intestine.
Fig. 6. Effects of sitagliptin (STG) on intestinal ulcer formation in rats. The small intestine was divided into 7 segments: 1 duodenal, 2 jejunal, and
4 ileal segments. Intestinal ulcers were induced by indomethacin (IM) treatment (10 mg/kg, s.c.). Representative macroscopic images of small
intestinal ulcers are shown; A: Vehicle + IM, B: STG (3 mg/kg, i.g.) + IM, C: STG (3 mg/kg, i.g.) + GLP2333 (100 μg/kg, s.c.) + IM. D: Total ulcer scores.
STG pretreatment reduced total ulcer score, whereas GLP2333 partially reversed the effects of STG. *p<0.05 vs vehicle + IM group, 
†p<0.05 vs STG
(3 mg/kg, i.g.) + IM group.
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inhibition combined with luminal nutrients may be an attractive
candidate for regulating intestinal mucosal GLP concentrations,
and may be therapeutically useful for the treatment of NSAID-
induced intestinal injury.
DPP4 is a member of the serine protease family, which also
includes DPP8 and DPP9.(10) DPP4 cleaves a number of regulatory
factors including hormones and cytokines.(29) Since the insulino-
tropic hormone GLP-1 is rapidly degraded and deactivated by
Fig. 7. Effects of sitagliptin (STG) on epithelial apoptosis in the ilea of indomethacin (IM)treated rats. A grossly normal ileum lesion was immuno
stained for singlestranded DNA (A–C; left ×100, right ×200) and immunoblotted for cleaved Caspase3 (D). A: control, B: Vehicle + IM, C: STG
(3 mg/kg, i.g.) + IM.
Fig. 8. Effects of sitagliptin (STG) on intestinal ulcer healing in rats.
Intestinal ulcers induced by indomethacin (IM, 8 mg/kg, s.c., once per
day on Days 0 and 1) were assessed on Day 8 with or without daily treat
ment with vehicle (Veh), an elemental diet (ED) and/or STG (3 mg/kg, i.g.)
from Day 2 to Day 8. ED + STG treatment significantly reduced total
ulcer score on Day 8. Coadministration of GLP2333 (100 μg/kg/day, sc,
for 7 days) partially reversed the healing effect of ED + STG on the
intestinal ulcers. *p<0.05 vs IM + Veh, †p<0.05 vs IM + ED, ‡p<0.05 vs
IM + STG, §p<0.05 vs IM + ED + STG.
Fig. 9. Mucosal concentration of total GLP2 in the ilea of indomethacin
(IM)treated rats during ulcer healing. IM treatment on Days 0 and 1
reduced total GLP2 concentration in the ileum on Day 8. An elemental
diet (ED) and ED + sitagliptin (STG) treatment significantly reversed the
reduced concentration of total GLP2. *p<0.05 vs vehicle (Veh), †p<0.05
vs IM + Veh.
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DPP4, DPP4 inhibitors have recently emerged as a treatment for
type 2 diabetes. These orally active drugs increase active serum
GLP-1 concentrations, which in turn increase insulin secretion
and improve glycemic control.(30) GLP-2, which like GLP-1 is
derived from proglucagon in enteroendocrine L cells, enhances
intestinal ion secretion and cell growth, and is clinically useful for
the treatment of short bowel syndrome and Crohn’s disease.(31,32)
Since GLP-2 is also rapidly degraded and deactivated by DPP4,
inhibition of DPP4 has been considered a novel approach for the
treatment of inflammatory bowel disease.(10) Our study revealed
high levels of expression of DPP4 mRNA in jejunal and ileal
mucosa, but not in colonic mucosa.
Although higher levels of expression of DPP8 and DPP9
mRNA were detected in the colon than in the small intestine, DPP
activity was much higher in the small intestine than in the colon.
Moreover, the DPP4 inhibitor STG significantly suppressed
mucosal DPP activity in the jejunum and ileum, but not in the
colon. These results suggest that DPP enzymatic activity in the
colon is mainly a result of DPP8 and DPP9 activity, whereas
DPP activity in the small intestine corresponds to DPP4 activity.
Therefore, DPP4 inhibitors likely selectively enhance local jejunal
and ileal GLP-2 concentrations but may have little effect on
colonic local GLP-2 concentrations. Similar results of mRNA and
enzyme activities were observed in rat intestine (data not shown).
Similar results of mRNA and enzyme activities were observed in
rat intestine (data not shown). Yu et al.(33) reported high expression
of DPP8 and DPP9 in the colon that was upregulated in DPP4
knockout mice. Since compensatory upregulation implies over-
lapping enzyme function, it is likely that the DPP family members
are functionally similar.(33) Using an experimental colitis model in
mice, Geier et al.(13) and Yazbeck et al.(34) also found that DPP4
knockout mice still exhibit significant DPP activity, again likely
due to compensatory upregulation. Therefore, DPP4 inhibition
may not be suitable for treatment of inflammatory diseases of the
colon, but useful for ileal diseases, where DPP4 is predominant.
Mucosal DPP4 activity was significantly decreased by oral
administration of STG, which significantly elevated the ileal
mucosal concentration of GLP-17-36. STG treatment prevented
intestinal ulcer formation and potentiated ED-induced promotion
of ulcer healing via the ileal GLP-2 pathway, suggesting that STG
may increase mucosal GLP-2 concentrations. These results
suggest that STG may be clinically useful for the treatment of ileal
diseases, such as Crohn’s disease and NSAID-induced enteritis.
STG treatment did not alter mucosal GLP-2 concentrations,
presumably because only total GLP-2 was measured. The mea-
surement of bioactive GLP-2 will clarify whether DPP4 inhibition
increases mucosal active GLP-2 concentrations as it does for
active GLP-1.
Interestingly, plasma concentrations of GLP-17-36 were also
elevated, even though STG administration reduced mucosal DPP
activity, but did not significantly suppress plasma DPP activity.
Therefore, intestinal mucosal DPP4 activity rather than plasma
DPP activity may primarily regulate plasma GLP concentration.
Inhibition of mucosal DPP4 activity may potentiate the local
effects of GLP-2 in small intestine.
In conclusion, mucosal DPP4 inhibition may effectively treat
NSAID-inducedsmall intestinal ulcers via activation of the GLP-2
pathway. ED treatment promoted intestinal ulcer healing and
augmented mucosal GLP-2 concentrations, enhanced by DPP4
inhibition, suggesting that the combination of DPP4 inhibition
with luminal amino acids may be therapeutic for ileal diseases,
such as intestinal Crohn’s disease and NSAID-induced enteropathy.
Abbreviations
DC distal colon
DPP4 dipeptidyl peptidase 4
ED elemental diet
GIP gastric inhibitory polypeptide/glucose-dependent insuli-
notropic peptide
GLP glucagon-like peptide
IM indomethacin
NSAIDs non-steroidal anti-inflammatory drugs
PC proximal colon
ssDNA single-stranded DNA
STG sitagliptin
TBST Tris-buffered saline with Tween
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